Fed. Circ. Unwinds Ineligibility Ruling For Gene Therapy IP

By Theresa Schliep · February 20, 2026, 6:48 PM EST

The Federal Circuit on Friday saved Regenxbio and the University of Pennsylvania's gene therapy patent, finding that splicing together genes from different organisms results in a molecule that is "markedly different...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

REGENXBIO Inc. v. Sarepta Therapeutics, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

January 31, 2024

Recent Articles By Theresa

February 04, 2026
Squires Throws Out 23 Patent Challenges, Grants 12
January 26, 2026
Masimo Chafes Against Apple's Bid To Duck $634M IP Verdict
January 20, 2026
Fed. Circ. Revives Inventor's Spinal Patent Case Against DePuy
December 02, 2025
Defamation Litigation Roundup: FDA, Lively, Alexander Bros.
November 26, 2025
USPTO, DOJ Tell ITC To Limit Exceptions In Netlist Case
November 20, 2025
Where Apple And Masimo's Watch Patent Fight Stands Now
November 14, 2025
ITC To Scrutinize Redesigned Apple Watch In Masimo IP Fight
October 28, 2025
Apple Spared From Some Masimo Patent Claims Before Trial
October 17, 2025
Mixed Discretionary Denial Batch Caps Off Big Week For PTAB
October 06, 2025
High Court Turns Down 6 Patent Cases At Start Of Term